To confirm findings in primary cells from PD patients, we used skin fibroblasts and assessed p-S65-Ub levels in carriers of homozygous PINK1 (p.Q456X) or compound heterozygous PRKN (p.R275W/ΔEx2) mutations relative to healthy controls. Here, PRKN is linked to Parkinson disease.